Liossis, S N C <br/><br/>
Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease.  [electronic resource] 

 -  Rheumatology (Oxford, England)  Aug 2006 
 - 1005-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>1462-0324 
<br/><br/><label>Standard No.: </label>10.1093/rheumatology/kei211  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Anti-Inflammatory Agents, Non-Steroidal--adverse effects<br/>Drug Therapy, Combination<br/>Female<br/>Glucocorticoids--therapeutic use<br/>Humans<br/>Male<br/>Middle Aged<br/>Mycophenolic Acid--adverse effects<br/>Prednisolone--therapeutic use<br/>Prospective Studies<br/>Pulmonary Diffusing Capacity--drug effects<br/>Pulmonary Fibrosis--diagnostic imaging<br/>Scleroderma, Diffuse--complications<br/>Tomography, X-Ray Computed<br/>Treatment Failure<br/>Vital Capacity--drug effects